Dark

Check out our Level2View

CDAK
Codiak BioSciences, Inc. Common Stock
stock NASDAQ

Inactive

Apr 4, 2023

0.0570USD-55.985%(-0.0725)14,634,710

Pre-market

0.00USD-100.000%(-0.13)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 6, 2022

09:00AM EST Codiak BioSciences to Present at the H.C. Wainwright Virtual GlobeNewswire Inc

Dec 2, 2021

12:07PM EST Codiak's COVID-19 Vaccine Hopeful Shows Potential In Preclinical Study Benzinga

08:30AM EST Codiaks Engineered Exosomes Promote T Cell and GlobeNewswire Inc

Dec 1, 2021

04:05PM EST Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference. Details are as follows: GlobeNewswire Inc

Nov 30, 2021

04:48PM EST Codiak BioSciences Announces FDA Clearance Of IND For exoASO-STAT6; Patient Dosing Expected 1H 2022 Benzinga

08:30AM EST Codiaks first engineered exosome therapeutic candidate for systemic administration GlobeNewswire Inc

Nov 16, 2021

06:48AM EST Codiak Reports Initial Data For exoSTING Phase 1/2 Trial Benzinga

06:45AM EST exoSTING resulted in localized STING pathway activation and dose-dependent immune activation GlobeNewswire Inc

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:16AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:15AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:14AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:10AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:09AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:00AM EST exoSTING monotherapy suppressed tumor growth and improved overall survival in a preclinical model of leptomeningeal disease, an aggressive metastasis of cancer to the central nervous system GlobeNewswire Inc

Nov 5, 2021

09:22AM EDT Codiak BioSciences Q3 EPS $(0.97) Up From $(12.83) YoY, Sales $1.16M Up From $954.00K YoY Benzinga

Nov 2, 2021

10:54AM EDT Lonza to Acquire Codiak's Exosomes Manufacturing Facility And Establish; Codiak To Receive ~$65M Of In-Kind Manufacturing Services For Its Clinical-Stage Programs And Retain Core Exosome Engineering And Loading Expertise Benzinga

08:00AM EDT Lonza to Acquire Codiak BioSciences Exosomes Manufacturing GlobeNewswire Inc

Oct 13, 2021

10:12AM EDT Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize PR Newswire

Oct 1, 2021

08:02AM EDT Codiak To Present Preclinical Data Demonstrating New Potential Therapeutic Applications Of Engineered Exosomes At Society For Immunotherapy Of Cancer (SITC) Annual Meeting Benzinga

08:00AM EDT Codiak to Present Preclinical Data Demonstrating New Potential GlobeNewswire Inc

Sep 23, 2021

09:22AM EDT Codiak BioSciences Files For U.S. Patent Titled 'METHODS OF SUPPRESSING DELIVERY OF EXOSOMES TO LIVER AND SPLEEN' Benzinga

Aug 18, 2021

08:30AM EDT Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of GlobeNewswire Inc

Aug 5, 2021

04:50PM EDT Codiak BioSciences Q2 EPS $(0.99), Sales $890.00K Up From $187.00K YoY Benzinga

Jul 7, 2021

08:30AM EDT Codiak BioSciences to Present at the Virtual William Blair Biotech GlobeNewswire Inc

Jul 6, 2021

04:30PM EDT Codiak BioSciences Announces the Transition of Benny Sorensen, M.D GlobeNewswire Inc

Jun 15, 2021

08:00AM EDT Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer GlobeNewswire Inc

Jun 2, 2021

08:30AM EDT Codiak BioSciences to Present at the Goldman Sachs 42nd Annual GlobeNewswire Inc

May 25, 2021

06:01AM EDT Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological PR Newswire

May 20, 2021

04:05PM EDT Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to GlobeNewswire Inc

May 19, 2021

09:46AM EDT Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening RTTNews

09:04AM EDT Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat PR Newswire

May 11, 2021

08:21AM EDT Codiak BioSciences Highlights Preclinical Data Of Co's Engineered Exomes Benzinga

08:00AM EDT New Preclinical Data Demonstrate Potential of GlobeNewswire Inc

May 10, 2021

08:00AM EDT Former Principal Investigator at MD Anderson Cancer Center and immuno-oncology drug developer at Novartis joins Codiak leadership GlobeNewswire Inc

May 6, 2021

04:16PM EDT Codiak BioSciences Q1 Sales $13.19M Up From $134.00K YoY Benzinga

04:01PM EDT Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12 and exoSTING, expected this year GlobeNewswire Inc

Apr 27, 2021

04:46PM EDT Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy Annual Meeting Benzinga

Apr 22, 2021

07:20AM EDT Data from Codiak's exoSTING Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology Benzinga

07:00AM EDT exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo GlobeNewswire Inc

Apr 12, 2021

10:14AM EDT Codiak BioSciences Saturday Morning Announced New Data Demonstrating Potential Of Engineered Exosomes To Enhance Therapeutic Index Of Well-Validated Cancer Immunotherapy Pathways At American Association For Cancer Research Conference Benzinga

10:13AM EDT Codiak BioSciences Saturday Morning Announced New Data Demonstrating Potential Of Engineered Exosomes To Enhance Therapeutic Index Of Well-Validated Cancer Immunotherapy Pathways Benzinga

Apr 10, 2021

08:30AM EDT exoASO-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021 GlobeNewswire Inc

Apr 8, 2021

04:28PM EDT Codiak BioSciences And Jazz Pharmaceuticals On Apr. 2 Mutually Agreed To Discontinue Work On Mutually exoASO-STAT3; Companies Will Continue To Jointly Advance Their R&D Efforts On Other Exosome-Based Therapeutic Programs Benzinga

Mar 30, 2021

09:30AM EDT Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion PR Newswire

Mar 17, 2021

07:38AM EDT Codiak BioSciences Q4 Loss Per Share $1.14 Vs Loss $8.37 Last Year RTTNews

07:32AM EDT Codiak BioSciences Q4 EPS $(1.14) Beats $(1.54) Estimate, Sales $1.64M Up From $150.00K YoY Benzinga

07:30AM EDT First human proof-of-concept data from exoIL-12 program confirmed desired product profile and enabled dose selection for further evaluation in patients GlobeNewswire Inc

Mar 10, 2021

04:40PM EST Codiak To Present Data From Its Two Novel Engineered Exosome Therapeutic Candidate Programs At The AACR Annual Meeting Benzinga

04:38PM EST Healthy volunteer clinical data for exoIL-12 accepted as alate-breaking abstract GlobeNewswire Inc

Feb 25, 2021

07:01AM EST Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire

Feb 17, 2021

04:30PM EST Codiak Announces Closing of $66.4 Million Public Offering, GlobeNewswire Inc

Feb 12, 2021

05:57AM EST Codiak Priced 2.75M Share Public Offering of Common Stock @$21/Share Benzinga

Feb 11, 2021

10:18PM EST Codiak Announces Pricing of $57.8 Million Public Offering of GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

04:19PM EST Codiak Biosciences Reports Offering Of 2.5M In Common Shares Benzinga

04:17PM EST Codiak Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Feb 4, 2021

07:33AM EST Codiak Reports Additional Positive Phase 1 Results For exoIL-12; Says 'Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity' Benzinga

07:30AM EST Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity GlobeNewswire Inc

Jan 21, 2021

09:00AM EST New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties GlobeNewswire Inc

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Dec 30, 2020

07:00AM EST exoIL-12 resulted in no local or systemic treatment-related adverse events GlobeNewswire Inc

Dec 21, 2020

09:00AM EST exoIL-12 has demonstrated tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo GlobeNewswire Inc

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Nov 23, 2020

07:30AM EST Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Details are as follows: GlobeNewswire Inc

Nov 19, 2020

04:07PM EST Codiak BioSciences Q3 EPS $(12.83), Sales $1.00M Benzinga

04:05PM EST Human clinical testing now underway with Codiaks first two candidates, exoIL-12 and exoSTING GlobeNewswire Inc

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 9, 2020

09:38AM EST Benzinga's Top Upgrades, Downgrades For November 9, 2020 Benzinga

08:25AM EST Codiak Presents Preclinical Data At SITC 2020 Demonstrating Potential Of EngEx Engineered Exosomes To Stimulate Targeted, Integrated Anti-Tumor Immunity Benzinga

08:00AM EST exoIL-12 demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo GlobeNewswire Inc

07:49AM EST Wedbush Initiates Coverage On Codiak BioSciences with Outperform Rating, Announces Price Target of $19 Benzinga

06:10AM EST Goldman Sachs Initiates Coverage On Codiak BioSciences with Buy Rating, Announces Price Target of $29 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 14, 2020

11:32AM EDT Codiak Biosciences Shares Open At $14.10, IPO Priced At $15.00/Share Benzinga

09:34AM EDT Codiak BioSciences Shares Expected To Open For Trade Today, IPO Priced At $15.00/Share Benzinga

Oct 13, 2020

07:04PM EDT Codiak Announces Pricing of Initial Public Offering Business Wire

Oct 11, 2020

06:35PM EDT IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week Benzinga

Share